Discrepancies between Protease Inhibitor Concentrations and Viral Load in Reservoirs and Sanctuary Sites in Human Immunodeficiency Virus-Infected Patients, Antimicrobial Agents and Chemotherapy, vol.47, issue.1, pp.238-281, 2003. ,
DOI : 10.1128/AAC.47.1.238-243.2003
Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous System, Archives of Neurology, vol.65, issue.1, pp.65-70, 2008. ,
DOI : 10.1001/archneurol.2007.31
Indinavir Trough Concentration as a Determinant of Early Nephrolithiasis in HIV-1-Infected Adults, Therapeutic Drug Monitoring, vol.29, issue.2, pp.164-70, 2007. ,
DOI : 10.1097/ftd.0b013e318030839e
URL : https://hal.archives-ouvertes.fr/inserm-00168427
HIV-protease inhibitors, N Engl J Med, vol.338, pp.1281-92, 1998. ,
Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with Ritonavir, The Journal of Clinical Pharmacology, vol.11, issue.suppl 1, pp.106-117, 1998. ,
DOI : 10.1002/j.1552-4604.1998.tb04398.x
Erratum to Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents, Clinical Pharmacokinetics, vol.35, issue.6, pp.275-91, 1998. ,
DOI : 10.1007/BF03259712
Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial, Journal of Antimicrobial Chemotherapy, vol.61, issue.1, pp.200-205, 2008. ,
DOI : 10.1093/jac/dkm413
Impact of Different Low-Dose Ritonavir Regimens on Lipids, CD36, and Adipophilin Expression, Clinical Pharmacology & Therapeutics, vol.829, issue.4, pp.375-885, 2009. ,
DOI : 10.1038/clpt.2008.243
Population Pharmacokinetics of Indinavir in Patients Infected with Human Immunodeficiency Virus, Antimicrobial Agents and Chemotherapy, vol.48, issue.9, pp.3226-3258 ,
DOI : 10.1128/AAC.48.9.3226-3232.2004
Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy, Fundamental and Clinical Pharmacology, vol.40, issue.3, pp.373-83, 2005. ,
DOI : 10.1097/00002030-200305230-00007
Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients, British Journal of Clinical Pharmacology, vol.24, issue.3, pp.276-86, 2005. ,
DOI : 10.1067/mcp.2002.121424
Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients, British Journal of Clinical Pharmacology, vol.58, issue.3, pp.353-62, 2007. ,
DOI : 10.1111/j.1742-7843.2006.pto_249.x
Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy, AIDS, vol.19, issue.18, pp.2127-2158, 2005. ,
DOI : 10.1097/01.aids.0000196122.91633.04
Pharmacogenetic Characteristics of Indinavir, Zidovudine, and Lamivudine Therapy in HIV-Infected Adults, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.42, issue.4, pp.441-490, 2006. ,
DOI : 10.1097/01.qai.0000225013.53568.69
Genetic contribution to variable human CYP3A-mediated metabolism, Advanced Drug Delivery Reviews, vol.54, issue.10, pp.1271-94, 2002. ,
DOI : 10.1016/S0169-409X(02)00066-2
Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy, HIV Medicine, vol.12, issue.1, pp.37-43, 2002. ,
DOI : 10.1097/00002030-199811000-00024
Indinavir Plasma Concentration and Adherence Score Are Codeterminant of Early Virologic Response in HIV-Infected Patients of the APROCO Cohort, Therapeutic Drug Monitoring, vol.27, issue.1, pp.63-70, 2005. ,
DOI : 10.1097/00007691-200502000-00013
Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients, Aids, vol.13, issue.4, pp.473-78, 1999. ,
DOI : 10.1097/00002030-199903110-00005
Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen - ANRS 111 trial, Fundamental & Clinical Pharmacology, vol.42, issue.Suppl. 1, 2008. ,
DOI : 10.1111/j.1472-8206.2009.00693.x
URL : https://hal.archives-ouvertes.fr/inserm-00416211
Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients, British Journal of Clinical Pharmacology, vol.100, issue.4, pp.548-57, 2008. ,
DOI : 10.1097/00002030-200001070-00007
URL : https://hal.archives-ouvertes.fr/inserm-00383731
The Dynamic of Adherence to Highly Active Antiretroviral Therapy: Results From the French National APROCO Cohort, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.28, issue.3, pp.232-271, 2001. ,
DOI : 10.1097/00042560-200111010-00005
Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects, Clinical Pharmacology & Therapeutics, vol.69, issue.3, pp.169-74, 2001. ,
DOI : 10.1067/mcp.2001.114164
The CYP3A4*1B allele increases risk for small cell lung cancer, Pharmacogenetics, vol.13, issue.10, pp.607-625, 2003. ,
DOI : 10.1097/00008571-200310000-00004
Hardy, Weinberg and language impediments, Genetics, vol.152, pp.821-846, 1999. ,
Inference of population structure using multilocus genotype data, Genetics, vol.155, pp.945-59, 2000. ,
Maximum likelihood estimation in nonlinear mixed effects models, Computational Statistics & Data Analysis, vol.49, issue.4, pp.1020-1058, 2005. ,
DOI : 10.1016/j.csda.2004.07.002
MONOLIX (MOdèles NOn LInéairesLInéaires`LInéairesà effets miXtes). MONOLIX group, 2008. ,
Estimation of Population Pharmacokinetic Parameters of Saquinavir in HIV Patients with the MONOLIX Software, Journal of Pharmacokinetics and Pharmacodynamics, vol.32, issue.2, pp.229-278, 2007. ,
DOI : 10.1007/s10928-006-9043-z
URL : https://hal.archives-ouvertes.fr/inserm-00156907
Bayesian data analysis, 1995. ,
Comparison of Model-Based Tests and Selection Strategies to Detect Genetic Polymorphisms Influencing Pharmacokinetic Parameters, Journal of Biopharmaceutical Statistics, vol.5, issue.6, pp.1084-102, 2008. ,
DOI : 10.1111/j.1525-1438.2006.00593.x
URL : https://hal.archives-ouvertes.fr/inserm-00339183
High Variability of Indinavir and Nelfinavir Pharmacokinetics in HIV-Infected Patients with a Sustained Virological Response on Highly Active Antiretroviral Therapy, Clinical Pharmacokinetics, vol.30, issue.12, pp.1267-78, 2005. ,
DOI : 10.2165/00003088-200544120-00005
Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the ???Cocktail??? Approach, Clinical Pharmacology & Therapeutics, vol.75, issue.2, pp.270-83, 2007. ,
DOI : 10.1038/sj.clpt.6100050
HIV-1 Protease Inhibitor, Ritonavir: A Potent Inhibitor of CYP3A4, Enhanced the Anticancer Effects of Docetaxel in Androgen-Independent Prostate Cancer Cells In vitro and In vivo, Cancer Research, vol.64, issue.20, pp.7426-7457, 2004. ,
DOI : 10.1158/0008-5472.CAN-03-2677
Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs, Clinical Pharmacokinetics, vol.20, issue.3, pp.279-283, 2005. ,
DOI : 10.2165/00003088-200544030-00005
Clinical Pharmacokinetics of Darunavir, Clinical Pharmacokinetics, vol.10, issue.3, pp.739-56, 2007. ,
DOI : 10.2165/00003088-200746090-00002
The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer, Pharmacogenetics, vol.12, issue.5, pp.355-66, 2002. ,
DOI : 10.1097/00008571-200207000-00003
Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo, Clinical Pharmacology & Therapeutics, vol.77, issue.5, pp.373-87, 2005. ,
DOI : 10.1016/j.clpt.2004.11.112
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus, Clinical Pharmacology & Therapeutics, vol.74, issue.3, pp.245-54, 2003. ,
DOI : 10.1016/S0009-9236(03)00168-1
Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms, Clinical Pharmacology & Therapeutics, vol.79, issue.6, pp.570-80, 2006. ,
DOI : 10.1016/j.clpt.2006.02.003
Increased transcriptional activity of theCYP3A4*1B promoter variant, Environmental and Molecular Mutagenesis, vol.259, issue.4, pp.299-305, 2003. ,
DOI : 10.1002/em.10199
Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: Study design and model???independent data analysis, Journal of Pharmaceutical Sciences, vol.88, issue.5, pp.568-73, 1999. ,
DOI : 10.1021/js9802392
Model-based Analysis of the Pharmacokinetic Interactions Between Ritonavir, Nelfinavir, and Saquinavir after Simultaneous and Staggered Oral Administration, Drug Metabolism and Disposition, vol.30, issue.12, pp.1455-61 ,
DOI : 10.1124/dmd.30.12.1455
Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients, British Journal of Clinical Pharmacology, vol.9, issue.2, pp.174-82, 2005. ,
DOI : 10.1067/mcp.2002.123553
The binding of HIV-1 protease inhibitors to human serum proteins, Biophysical Chemistry, vol.105, issue.2-3, pp.221-251, 2003. ,
DOI : 10.1016/S0301-4622(03)00071-1
Effect of ??1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro, British Journal of Clinical Pharmacology, vol.39, issue.1, pp.99-102, 2001. ,
DOI : 10.1046/j.1365-2125.2001.01324.x
???Acid Glycoprotein Concentration on the Antiviral Efficacy of Human Immunodeficiency Virus Protease Inhibitors, The Journal of Infectious Diseases, vol.180, issue.6, pp.1833-1870, 1999. ,
DOI : 10.1086/315123
Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model, Computational Statistics & Data Analysis, vol.51, issue.3, pp.1562-74, 2006. ,
DOI : 10.1016/j.csda.2006.05.007
URL : https://hal.archives-ouvertes.fr/inserm-00182360
Pharmacologic Considerations for Therapeutic Success with Antiretroviral Agents, Annals of Pharmacotherapy, vol.338, issue.9, pp.989-95, 1999. ,
DOI : 10.1345/aph.19075
A Retrospective, Cohort-Based Survey of Patients Using Twice-Daily Indinavir + Ritonavir Combinations: Pharmacokinetics, Safety, and Efficacy, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.26, issue.3, pp.218-242, 2001. ,
DOI : 10.1097/00126334-200103010-00003
A Critical Evaluation of the Therapeutic Range of Indinavir, Annals of Pharmacotherapy, vol.1, issue.7-8, pp.1230-1267, 2002. ,
DOI : 10.1345/aph.1A016
Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors, AIDS, vol.13, issue.10, pp.63-70, 1999. ,
DOI : 10.1097/00002030-199907090-00001